Abstract

A recent fixed combination of amlodipine (AML) besylate, olmesartan (OLM) medoxomil and hydrochlorothiazide (HCT) has been marketed for the treatment of hypertension. The bioanalysis of this mixture is a challenge due to the diverse physicochemical properties. The aim of this study is to develop a method using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the simultaneous bioanalysis of the mixture in human plasma.A mobile phase of 10 mM ammonium formate containing 0.1% formic acid: methanol: acetonitrile (35:50:15, v/v/v) was recruited for the chromatographic separation of the mixture on a Zorbax SB-Aq (150×4.6 mm, 5 µm) column. The deutrated analogues of AML, OLM and HCT were used as the internal standards (IS). Polarity switching SRM transitions in positive-mode for AML, OLM, and negative-mode for HCT were applied for detection. Sequential double liquid-liquid extraction (SdLLE) was adopted for sample preparation. The developed method was fully validated and applied for the determination of AML, OLM and HCT following a single oral administration of 5/20/12.5 mg of AML, OLM and HCT, respectively tablets to healthy volunteers (n = 30).The developed method was linear (r2> 0.99), accurate (105 - 90%), precise (CV% <11.92) and specific for the determination of AML, OLM and HCT over the concentration range of 0.1–15, 5–1200 and 2–150 ng/mL. The adopted SdLLE resulted into reproducible extraction recoveries of 75%, 63% and 83% for AML, OLM and HCT, respectively. The pharmacokinetic analysis revealed uniform profile in the subjects which were comparable to previously reported results in other populations.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call